Edotreotide gallium Ga-68
- Generic Name
- Edotreotide gallium Ga-68
- Drug Type
- Small Molecule
- Chemical Formula
- C65H89GaN14O18S2
- CAS Number
- 2101630-92-4
- Unique Ingredient Identifier
- Y68179SY2L
- Background
Edotreotide gallium Ga-68 is an 8 amino acid peptide bound to the chelator 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA). Edotreotide gallium Ga-68 is indicated for localizing somatostatin receptor positive neuroendocrine tumors by positron emission tomography. Dotatate gallium Ga-68 is used for a similar indication. Dotatate gallium Ga-68 has lower tumor uptake but this data is highly variable between patients.
Edotreotide gallium Ga-68 was granted FDA approval on 21 August 2019.
- Indication
Edotreotide gallium Ga-68 is a radioactive diagnostic compound used in positron emission tomography (PET) for diagnose somatostatin receptor positive neuroendocrine tumors in pediatrics and adults.
- Associated Conditions
- Neuroendocrine Tumors
68Ga-DOTA-TOC PET/CT in Imaging Participants With Neuroendocrine Tumors
- Conditions
- Somatostatin Positive Neoplastic Cells PresentVon Hippel-Lindau SyndromeNeuroendocrine NeoplasmMeningiomaMetastatic Well Differentiated Neuroendocrine NeoplasmMultiple Endocrine Neoplasia Type 1
- Interventions
- Procedure: Computed TomographyProcedure: Positron Emission Tomography
- First Posted Date
- 2016-12-23
- Last Posted Date
- 2021-02-15
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 4
- Registration Number
- NCT03001349
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
GA-68 DOTA-TOC of Somatostatin Positive Malignancies
- Conditions
- Neuroendocrine TumorCarcinoid TumorsNeuroblastomaParaganglioma
- Interventions
- Procedure: Computed Tomography (CT)Procedure: Magnetic Resonance Imaging (MRI)Procedure: Positron Emission Tomography (PET)
- First Posted Date
- 2014-06-30
- Last Posted Date
- 2019-11-12
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 300
- Registration Number
- NCT02177773
- Locations
- 🇺🇸
University of California, San Francisco, San Francisco, California, United States
Comparative Study of Sensitivity of Ga-DOTATOC PET vs Octreoscan SPECT + CT
- Conditions
- Adult MedulloblastomaSomatostatinomaNeuroblastomaChildhood MedulloblastomaNeuroendocrine Tumor
- Interventions
- Procedure: positron emission tomography/computed tomographyRadiation: indium In 111 pentetreotideProcedure: computed tomographyProcedure: contrast-enhanced magnetic resonance imaging
- First Posted Date
- 2013-06-05
- Last Posted Date
- 2021-09-22
- Lead Sponsor
- Sue O'Dorisio
- Target Recruit Count
- 68
- Registration Number
- NCT01869725
- Locations
- 🇺🇸
University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.